Disease management
The funding will be used to secure FDA clearance for its benchtop blood-testing system for use in doctor's offices, clinics and pharmacies.
The companies will create a value-based care program to support cardiology patients and providers at health systems and CINs.
Also, Kakao Healthcare is extending access to its AI to a public diabetes screening programme in South Korea.
Patients in Switzerland will have access to Mika Health's psychological support offerings in conjunction with pharmaceutical therapy.
CALFREE uses input from optical sensors commonly found in smartwatches or commercial smartphones to collect blood pressure data.
Cardiac and lung-disease platform Eko Health secured $41 million in Series D funding.
Cancer patients and caregivers will receive free access to an AI-enabled app for mental health and other support services.
The company will use the funds to expand its cloud-based automation platform for providers and pharmaceutical companies.
The South Korean company now plans to expand the application of its AI to diagnose other medical conditions, including heart and neurological disorders.
The continuous glucose monitoring biosensor platform will use the funds to scale its manufacturing, move toward regulatory approval and perform more clinical trials.